Evidence map›Paper›PMID 28961381›Full record

Trial reportCNS neuroscience & therapeutics2017

Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy.

Said Dahbour, Fatima Jamali, Dana Alhattab, Ali Al-Radaideh, Osama Ababneh, Nosaiba Al-Ryalat, Muawyeh Al-Bdour, Bayan Hourani, Mohammed Msallam, Murad Rasheed and 4 more

Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in CNS neuroscience & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03765957 (Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells), which is not on this map. Cited by 68 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03765957 early_phase1unknown statusnot on this mapstarted 2019, after this paper: background citation

Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells

TypeinterventionalSponsorCentral South UniversityRan2019 to 2021Enrolled12ConditionsPsoriasisArmsMesenchymal Stem Cells
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Said DahbourDepartment of Neurology, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Fatima JamaliCell Therapy Center, The University of Jordan, Amman, Jordan.ORCID http://orcid.org/0000-0003-4032-5451
Dana AlhattabCell Therapy Center, The University of Jordan, Amman, Jordan.
Ali Al-RadaidehDepartment of Medical Imaging, Faculty of Allied Health Sciences, Hashemite University, Zarqa, Jordan.
Osama AbabnehDepartment of Ophthalmology, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Nosaiba Al-RyalatDepartment of Diagnostic Radiology and Nuclear Medicine, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Muawyeh Al-BdourDepartment of Ophthalmology, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Bayan HouraniCell Therapy Center, The University of Jordan, Amman, Jordan.
Mohammed MsallamDepartment of Ophthalmology, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Murad RasheedDepartment of Neurology, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Ammar HuneitiDepartment of Computer Information Systems, King Abdullah II School for Information Technology, The University of Jordan, Jordan.
Yacoub BahouDepartment of Neurology, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Emad TarawnehDepartment of Diagnostic Radiology and Nuclear Medicine, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Abdalla AwidiCell Therapy Center, The University of Jordan, Amman, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis open-label prospective phase I/IIa clinical study used autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) followed by mesenchymal stromal cells conditioned media (MSC-CM) for the first time to treat multiple sclerosis (MS) patients. The primary goal was to assess the safety and feasibility and the secondary was efficacy. The correlation between the MSC-CM content and treatment outcome was investigated.

methodsTen MS patients who failed conventional therapy were enrolled. Adverse events were recorded to assess safety. The Expanded Disability Status Scale (EDSS) was the primary efficacy measurement, the secondary included clinical (25WFT, 9-PHT), cognitive (MMS), ophthalmology (OCT, VEP), and radiological (MRI lesion and volume) tests. The MSCs-CM concentration of 27 inflammatory biomarkers was investigated.

resultsThe treatment protocol was well tolerated by patients. There was an overall trend of improvement in all the tests, except the lesion volume which increased significantly. A decrease of 4 and 3.5 points on the EDSS was achieved in two patients. We report a correlation between a decreased lesion number at baseline and higher IL-6, IL-8, and VEGF MSC-CM content.

conclusionThe used protocol was safe and feasible with possible efficacy. The addition of MSC-CM could be related to the magnitude of EDSS improvement observed.

Indexed as

Culture Media, ConditionedMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAdolescentAdultBrainCells, CulturedDisability EvaluationEvoked Potentials, VisualFemaleFollow-Up StudiesHumansImmunologic FactorsMagnetic Resonance ImagingMaleMiddle AgedCulture Media, ConditionedImmunologic Factorsconditioned mediaexpanded disability status scalemagnetic resonance imagingmesenchymal stem cellsmultiple sclerosisoptical coherence tomographyvisual evoked potential

Identifiers

PMID28961381
PMCPMC5698713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.